FOLH1 and neoplasm: An intrapatient dosimetry comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in four mCRPC patients reported that 177Lu-rhPSMA-10.1 delivered an average of 3.3 times (range, 1.2–8.3 times) higher absorbed radiation dose to individual tumor lesions compared to 177Lu-PSMA-I&T [15].